<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03870854</url>
  </required_header>
  <id_info>
    <org_study_id>CTO-PA #1723</org_study_id>
    <nct_id>NCT03870854</nct_id>
  </id_info>
  <brief_title>Paced Electrogram Feature Analysis (PEFA) for Ablation Targeting in Ischaemic Ventricular Tachycardia</brief_title>
  <acronym>PEFA-VT</acronym>
  <official_title>Paced Electrogram Feature Analysis (PEFA) for Ablation Targeting in Ischaemic Ventricular Tachycardia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Damian Redfearn</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Queen's University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Canadian multicentre prospective cohort study of 40 patients with ischaemic heart disease and
      therapy from an implantable cardioverter defibrillator (ICD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Paced Electrogram Feature Analysis is employed to elucidate VT isthmus sites and target Type
      I sites for ablation to prevent recurrent VT/VF.

      The trial hypothesis is: catheter ablation employing PEFA will, in comparison to published
      data, reduce the composite outcome of death at any time, appropriate ICD shock, ventricular
      tachycardia storm or treated sustained ventricular tachycardia below the detection rate of
      the ICD or incessant VT for patients with prior myocardial infarction and sustained
      ventricular tachycardia or fibrillation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 13, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a Canadian multi-centre prospective cohort study of 40 participants.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>3 years</time_frame>
    <description>a composite of death - any time post procedure myocardial infarction and sustained ventricular tachycardia or fibrillation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Appropriate ICD shock</measure>
    <time_frame>3 years</time_frame>
    <description>Time to first appropriate ICD shock - any time post procedure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VT storm</measure>
    <time_frame>3 years</time_frame>
    <description>Time to 3 or more episodes of VT within 24 hours - any time post procedure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treated sustained VT below the detection rate of the ICD</measure>
    <time_frame>3 years</time_frame>
    <description>Time to any sustained VT below the detection rate of the ICD; e.g. by external cardioversion, pharmacologic conversion, or manual ICD therapy - any time post procedure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incessant VT</measure>
    <time_frame>3 years</time_frame>
    <description>Time to incessant VT defined as a sustained ventricular arrhythmia which does not terminate despite appropriate external cardioversion/defibrillation or ICD antitachycardia pacing or shocks, or terminates but reinitiates within â‰¤5 seconds - any time post procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Appropriate anti-tachycardia pacing (ATP) from ICD</measure>
    <time_frame>3 years</time_frame>
    <description>Appropriate anti-tachycardia pacing (ATP) from ICD - any time post procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inducible for ventricular arrhythmia</measure>
    <time_frame>3 years</time_frame>
    <description>Number of inducible for ventricular arrhythmia following catheter ablation guided by PEFA protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ventricular arrhythmia events</measure>
    <time_frame>3 years</time_frame>
    <description>This is a composite of appropriate ATP, appropriate shock, sustained VT not treated by ICD, external cardioversion, or pharmacologic cardioversion, and incessant VT - any time during or after the procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Escalation and De-escalation of antiarrhythmic medication</measure>
    <time_frame>3 years</time_frame>
    <description>Any increase or decrease in the dosage of antiarrhythmic medication either due to inefficacy or side effects will be assessed - any time post procedure</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Ischemic Ventricular Tachycardia (VT)</condition>
  <arm_group>
    <arm_group_label>PEFA targeted substrate ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Use of PEFA strategy to identify and target VT isthmuses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PEFA VT ablation technique</intervention_name>
    <description>Catheter ablation guided by PEFA technique</description>
    <arm_group_label>PEFA targeted substrate ablation</arm_group_label>
    <other_name>Paced electrogram feature analysis or 'PEFA'</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  greater than 18 years of age

          -  Ischaemic heart disease and prior myocardial infarction (using the international
             definition of MI: Q waves or imaging evidence of regional myocardial akinesis/thinning
             in the absence of a non-ischemic cause with documentation of prior ischaemic injury)

          -  Eligible for catheter ablation as standard of care

          -  Implantable Cardioverter Defibrillator

        Exclusion Criteria:

          -  Unable or unwilling to provide consent

          -  Both mechanical aortic and mitral valve

          -  LV thrombus,

          -  NYHA class IV heart failure symptoms

          -  Contraindication to heparin

          -  Survival limited to &lt;1 year in estimation of attending care team,

          -  Prior VT ablation Exclusion to standard of care VT catheter ablation procedure such as

          -  Active ischaemia (acute thrombus diagnosed by coronary angiography, or dynamic ST
             segment changes demonstrated on ECG) or another reversible cause of VT (e.g. drug-
             induced arrhythmia), had recent acute coronary syndrome within 30 days thought to be
             due to acute coronary arterial thrombosis, or have CCS functional class IV angina.
             Note that biomarker level elevation alone after ventricular arrhythmias does not
             denote acute coronary syndrome or active ischemia.

          -  Non-ischaemic cardiomyopathy because of reduced ablation success and PEFA has not been
             examined in the context of a non-ischaemic cardiomyopathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Damian Redfearn</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kingston Health Sciences Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sharlene Hammond</last_name>
    <phone>613-533-2148</phone>
    <email>Sharlene.Hammond@kingstonhsc.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kingston Health Sciences Centre</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharlene Hammond</last_name>
      <phone>613-533-2148</phone>
      <email>Sharlene.Hammond@kingstonhsc.ca</email>
    </contact>
    <contact_backup>
      <email>KGHRI.CARU@kingstonhsc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Damian Redfearn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexander Porretta, HBSc</last_name>
      <phone>519-685-8500</phone>
      <phone_ext>32268</phone_ext>
      <email>Alexander.Porretta@lhsc.on.ca</email>
    </contact>
    <investigator>
      <last_name>Lorne Gula</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Heart Institutation</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Madhuri Thommandru</last_name>
      <phone>613-696-7000</phone>
      <phone_ext>19080</phone_ext>
      <email>mthommandru@ottawaheart.ca</email>
    </contact>
    <investigator>
      <last_name>Pablo Nery</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>March 6, 2019</study_first_submitted>
  <study_first_submitted_qc>March 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2019</study_first_posted>
  <last_update_submitted>August 28, 2019</last_update_submitted>
  <last_update_submitted_qc>August 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Queen's University</investigator_affiliation>
    <investigator_full_name>Dr. Damian Redfearn</investigator_full_name>
    <investigator_title>MB CHB MD MRCPI FRCPC Professor of Medicine, Kingston Health Sciences Centre</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

